Danaher Corporation is scheduled to release second-quarter 2026 results on July 21 before market open, with the Zacks Consensus Estimate for revenues pegged at $6.09 billion and earnings at $1.84 per share. The earnings estimate has risen a penny in the past seven days and implies a 2.2% increase from the year-ago quarter, while the revenue estimate indicates a 2.6% rise. The company's bottom line surpassed the consensus in each of the preceding four quarters, delivering an average beat of 6.7%. Zacks' model predicts another beat this time, as Danaher carries an Earnings ESP of +0.62% and a Zacks Rank of 2. Key drivers include strength in the bioprocessing business within the Biotechnology segment, where the consensus sales estimate is $1.95 billion, and the June 2026 acquisition of Masimo Corp. for $9.9 billion, which is expected to have enhanced the diagnostics portfolio. However, escalating costs and higher interest expenses may have weighed on profitability.
Masimo Corporationacquired by Danaher for $9.9 billion, enhancing diagnostics portfolio
Cardinal Health Inc
CVS Health Corp
Danaher Corporationexpected Q2 earnings beat with positive ESP and Zacks Rank 2
West Pharmaceutical Services Inc